Dr. Posadas Discusses Darolutamide in Castration-Resistant Prostate Cancer

Mar 29, 2019

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.

With enzalutamide (Xtandi) and apalutamide (Erleada) already available for the treatment of these patients, the bar was set high, and darolutamide clearly met this bar in terms of activity, Posadas says.

Darolutamide is a very different molecule, which lacks penetration of the central nervous system, and so far data support that this results in reduced toxicity. Posadas says it will be interesting to see how toxicity is impacted as more data become available.

Related Content